Epizyme Sells Its Shares For Up To 85 Million Dollars

Epizyme, Inc. is a fully integrated biopharmaceutical company focused on developing and commercializing novel epigenetic drugs. The company has announced a public offering to purchase up to 56,000,000 shares. In addition, the company has granted the underwriters an option to buy up to an additional 850,000 shares of its common stock. Proceeds from the offering will be used to fund the Company’s global development and commercializing activities for tazemetostat, including its ongoing Phase 1b/3 clinical trials in Japan and other countries.


Epizyme’s goal is to develop and commercialize tazemetostat for the treatment of patients with solid tumors and hematological malignancies. This financing will also support the Company’s efforts to identify additional product candidates and accelerate the commercialization of TAZVERIK. The offering is being made by a group of joint book-running managers led by Jefferies and Barclays. A shelf registration statement relating to the shares was previously filed with the US Securities and Exchange Commission. This offering is being made only through the written prospectus and accompanying prospectus.